- Conditions
- Antipsychotic-induced Weight Gain (AIWG)
- Interventions
- Miricorlilant, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–58
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Placebo, LY2140023
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 19
- States / cities
- Escondido, California • Garden Grove, California • Paramount, California + 16 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Risperidone, Exposure/ritual prevention therapy (EX/RP), Placebo
- Drug · Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- risperidone
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 60 more
- Conditions
- Schizophrenia
- Interventions
- Risperidone plus Placebo, Risperidone plus DMXB-A
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Schizophrenia
- Interventions
- MK-8189, Placebo, Background AAP Therapy
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia
- Interventions
- Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Drug
- Lead sponsor
- Rovi Pharmaceuticals Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
- Drug · Behavioral
- Lead sponsor
- Michael Aman
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, Risperdal
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Catonsville, Maryland
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
- Drug · Behavioral
- Lead sponsor
- Joseph Blader
- NIH
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas